nach oben

Tipp

Resectability of rectal cancer after neoadjuvant treatment – current status

verfasst von: M. Sabol, MD PhD, R. Donát, P. Chvalný, J. Palaj, D. Dyttert, P. Mračna, Š. Durdík

Erschienen in: European Surgery | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The purpose of the study was to compare our experience to recent trends of multimodal treatment of patients with locally advanced rectal cancer.

Patients and methods

209 patients with histologically proven adenocarcinoma of the rectum were treated for 3 years by a multimodal approach in a single center. Patients were evaluated for clinical and pathologic response. The type of surgical procedure and the number of retrieved lymph nodes and postoperative complications were recorded.

Results

Neoadjuvant Chemoradiotherapy (CRT) had a downstaging effect in more than half of our patients (50.61 %), and about one quarter of them achieved a complete pathologic response (22.22 %).

Conclusions

Preoperative CRT produced an encouraging down-staging effect with acceptable toxicity and perioperative complications.

Vorheriger Artikel Attitudes and compliance to the WHO Surgical Safety Checklist; a review

Nächster Artikel Cold-stored arterial allografts for in situ reconstruction of infected prosthetic grafts

Ferenschild FT, Dawson I, de Graaf EJ, de Wilt JH, Tetteroo GW. Preoperative radiotherapy has no value for patients with T2–3, N0 adenocarcinomas of the rectum. Dig Surg. 2009;26(4):291–296. doi:10.1159/000227771.. CrossRefPubMed

Rödel C, Trojan J, Bechstein WO, Woeste G. Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated? Dig Dis. 2012;30(2):102–108. doi:10.1159/000342038. CrossRefPubMed

Van Gijn, et al. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–582. CrossRefPubMed

Valentini V. Tumor regression grading in rectal cancer: is it time to move forward? J Clin Oncol. 2014;32(15):1534–1536. CrossRefPubMed

Kulu Y, Ulrich A, Buchler MW. Resectable rectal cancer: Which patient does not need preoperative radiotherapy? Dig Dis. 2012;30(2):118–125. CrossRefPubMed

Titel: Resectability of rectal cancer after neoadjuvant treatment – current status
verfasst von: M. Sabol, MD PhD
R. Donát
P. Chvalný
J. Palaj
D. Dyttert
P. Mračna
Š. Durdík
Publikationsdatum: 01.05.2016
Verlag: Springer Vienna
Erschienen in: European Surgery / Ausgabe Sonderheft 2/2016
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI: https://doi.org/10.1007/s10353-016-0404-6

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Resectability of rectal cancer after neoadjuvant treatment – current status

Abstract

Background

Patients and methods

Results

Conclusions

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Abstract

Background

Patients and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2016

Acute Superior Mesenteric Artery Occlusion – Combined Treatment Strategy

Surgical treatment of the progressive endoleak type II after EVAR

Comprehensive surgical care: less recognized factors in successfull operative treatment

Use of an anatomical self-gripping Progrip™ laparoscopic mesh in TAPP hernia repair. Possible standard? Preliminary results of a prospective study

New experience with the integrated and hybrid operating room at the Department of General, Visceral and Thoracic surgery

Attitudes and compliance to the WHO Surgical Safety Checklist; a review